Business

According to Spyryx Biosciences, Cystic Fibrosis Foundation Therapeutics (CFFT) will increase a development award to Spyryx to provide a total of up to $5 million. The company said that it plans to use the funds for its HOPE-1 Phase 2 study of SPX-101, an inhaled SPLUNC1-derived peptide, in CF patients. Earlier this year, Spyryx announced positive top line data … [Read more...] about Spyryx Biosciences gets additional funding for development of SPX-101 for CF

Consort Medical, parent company of device manufacturer Bespak and CDMO Aesica, has announced that its pre-tax profits for fiscal year 2017 almost doubled from FY 2016, rising from £11.3 million to £21.9 million. Bespak earnings before interest and taxes (EBIT) rose 3.9% and Aesica's EBIT rose 17.7%. Consort acquired Aesica in 2014, and in November 2015, the … [Read more...] about Consort Medical doubles pre-tax profit over previous fiscal year

Inhaled drug developer Pulmatrix announced that it has licensed a portfolio of kinase inhibitors from Janssen Biotech subsidiary RespiVert that it plans to develop as inhaled therapies for respiratory diseases. According to a form filed with the US Securities and Exchange Commission (SEC), Pulmatrix will pay $1 million up front plus milestones ranging from $1-80 … [Read more...] about Pulmatrix licenses kinase inhibitors from RespiVert

Windtree Therapeutics has signed an agreement with Hong-Kong based Lee's Pharmaceutical Limited for the development and commercialization of Aerosurf and other KL4 surfactant products in a number of Asian countries, the company said. Lee's will also have the right to manufacture KL4 surfactants in China, but aerosol products are excluded from that license. In … [Read more...] about Windtree partners with Lee’s Pharm for development of Aerosurf in Asia

The Grünenthal Group will acquire rights to all dosage forms of Zomig zolmitriptan for the treatment of migraines and cluster headaches, including Zomig nasal spray, from AstraZeneca for $200 million up front plus up to $102 million in future milestone payments the company said. The deal includes rights to market Zomig in all countries where it is approved except … [Read more...] about Grünenthal acquires global rights to Zomig nasal spray

Egalet Corporation has announced that Ascend Therapeutics will begin co-promoting Egalet's Sprix ketorolac tromethamine nasal spray to women's healthcare practitioners in the US in the third quarter of 2017 and will continue for at least two years. Financial terms of the deal were not disclosed. Sprix nasal spray was approved for the short term management of … [Read more...] about Ascend Therapeutics to co-promote Sprix ketorolac nasal spray

US grocer Albertsons will begin selling Lupin's InspiraChamber antistatic valved holding chamber exclusively in more than 1,700 pharmacies in 35 US states, Lupin has announced. The InspiraChamber spacer can be used with one of several pediatric face masks, including the SootherMask, which includes an opening for a child's pacifier. Lupin licensed the product from … [Read more...] about Albertsons to sell Lupin’s InspiraChamber exclusively in US

Horizon Pharma has agreed to sell Raptor Pharmaceuticals, which owns the rights to Quinsair levofloxacin inhalation solution in Europe, the Middle East and Africa, to Chiesi Farmaceutici for $70 million and potential sales-based milestone payments, the company said. Horizon will retain rights to Quinsair and another product, Procysbi, in the US, Canada, and Latin … [Read more...] about Chiesi to acquire Raptor Pharmaceuticals and its rights to Quinsair levofloxacin inhalation solution in EMEA regions

Windtree Therapeutics has received $900,000 from a Small Business Innovation Research Grant (SBIR) grant for Phase 2b trial of Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS) who are receiving nasal continuous positive airway pressure (nCPAP), the company said. In August 2016, Windtree announced that it had … [Read more...] about Windtree Therapeutics gets $900,000 from SBIR grant